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Abstract In this work, we propose that for further studies
of the physiopathology and treatment for inflammatory
bowel diseases, an integral view of the conditions,
including the triad of microbiota–heat shock proteins
(HSPs)–probiotics, ought to be considered. Microbiota is
the complex microbial flora that resides in the gut, affect-
ing not only gut functions but also the health status of the
whole body. Alteration in the microbiota’s composition has
been implicated in a variety of pathological conditions
(e.g., ulcerative colitis, UC), involving both gut and extra-
intestinal tissues and organs. Some of these pathologies are
also associated with an altered expression of HSPs (chap-
erones) and this is the reason why they may be considered
chaperonopathies. Probiotics, which are live microorgan-
isms able to restore the correct, healthy equilibrium of
microbiota composition, can ameliorate symptoms in
patients suffering from UC and modulate expression levels
of HSPs. However, currently probiotic therapy follows
ex-adiuvantibus criteria, i.e., treatments with beneficial effects
but whose mechanism of action is unknown, which should
be changed so the probiotics needed in each case are pre-
determined on the basis of the patient’s microbiota. Con-
sequently, efforts are necessary to develop diagnostic tools
for elucidating levels and distribution of HSPs and the
microbiota composition (microbiota fingerprint) of each
subject and, thus, guide specific probiotic therapy, tailored
to meet the needs of the patient. Microbiota fingerprinting
ought to include molecular biology techniques for
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sequencing highly conserved DNA, e.g., genes encoding
16S RNA, for species identification and, in addition,
quantification of each relevant microbe.
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Introduction
We argue that two parameters are essential in defining,
understanding, and diagnosing inflammatory bowel diseases
(IBD): the intestinal flora (microbiota) and heat shock pro-
teins (HSP), many of which are molecular chaperones. A
third pillar, which pertains to treatment, is probiotics. The
combination constitutes a triad that we propose as a blueprint
for future clinical and laboratory research.
Consequently, in the first three sections of this overview,
we introduce molecular chaperones and their pathologies
(chaperonopathies), the microbiota, and probiotics. In the
following sections, we discuss ulcerative colitis (UC), as an
illustrative example of our proposal, based on our work and
that of others in the literature. We hope to provide an
alternative standpoint to view UC that might reveal as yet
undisclosed aspects of pathogenesis and, thus, open the
way for the development of novel treatments, more effi-
cacious than those currently available.
Molecular chaperones and chaperonopathies
Molecular chaperones are a family of ancestral proteins
that have been conserved throughout evolution, being
present from bacteria and archaea to humans [1]. Many
molecular chaperones are heat shock proteins (HSPs) and
the terms are often used as synonyms in the literature,
although some HSPs are not chaperones and vice versa.
The entire complement of chaperones-HSPs of an organism
has been called the chaperoning system [2]. It is constituted
of chaperones, co-chaperones, and chaperone cofactors.
The main groups of chaperones are shown in Table 1.
Their typical function is to assist other proteins in folding
as well as in re-folding after stress, or in degradation after
irreversible misfolding [3]. However, during evolution,
some of them have acquired other, extrachaperoning
functions (e.g., apoptosis control [4]) and the property to be
actively secreted into the extracellular space. The secreted
chaperones may function in a paracrine/endocrine fashion,
for example, modulating the response of certain immune
system cells [5]. A few illustrative examples of reported
interactions between the chaperone HSP60 and the immune
system are displayed in Table 2. Since HSP-chaperones are
important for cell and tissue homeostasis, their structural
and/or functional defects can cause diseases of various
types affecting diverse tissues and organs; these pathologic
conditions are named chaperonopathies [3, 6].
Chaperonopathies, like many other groups of diseases,
can be classified in various ways [3, 7]. For instance, taking
into consideration the way they manifest themselves and
cause pathology, chaperonopathies can be classified into by
Table 1 Main HSP-chaperones classified according to their molec-
ular weight
MW (kDa) range Classical family
200 or higher Sacsin
100–199 HSP100/110
81–99 HSP90
65–80 HSP70/DnaK
55–64 HSP60 and CCT subunits
(chaperonins of Group I
and II, respectively)
35–54 HSP40/DnaJ
34 or less Small HSP (e.g., crystallins)
Modified from Macario et al. [5]
Table 2 Examples of reported interactions between HSP60 and the
immune system
Cells Receptor(s) Effect(s)
Adipocytes Unknown
(interacts with
HSP60 N-
terminus)
Adipocyte inflammation;
muscle cell insulin
resistance
Endothelial cells,
smooth muscle
cells, dendritic
cells
LOX-1 Cross-presentation on
MHC class I molecules
(?)
Macrophages TLR4 TNF-alpha production
Macrophages and
dendritic cells
Unknown (TLR4
independent)
IFN-alpha production that
leads to antigen-
dependent T cell release
of IFN-gamma
Myocardium TLR4 IRAK-1 activation
Neutrophilic
granulocytes
Unknown Production of ROS and
release of primary-
granule enzymes
Peripheral blood
mononuclear cells
Unknown TNF-alpha secretion
T cells CD30 IL-10 secretion
T cells TLR2 and/or
TCR
Tregs population
enhancement
T cells CD54 RA?
RO-
Proliferation
T cells TLR2 Down-regulation of
chemokines receptor
expression (CXCR4 and
CCR7)
Modified from Macario et al. [5] and updated
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excess, by defect, and by mistake or collaborationism.
Quantitative variations (i.e., excess or defect) in chaperone
levels may be due to various mechanisms, such as gene
overexpression, diminished mRNA or protein degradation,
and slower trafficking than normal through any given cell
compartment [6, 7]. However, some chaperonopathies
occur when a normal chaperone functions to favor a
pathogenic agent (e.g., virus or bacterium), or a pathologic
cell (e.g., a cancer cell), and its consequences, such as
inflammation. These chaperonopathies are called by mis-
take or collaborationism, since they act cooperating ‘‘trai-
torously’’ with the enemy, the disease-causing agent and
the disease itself, rather than with the host, the human body
[7].
Our group in the past proposed, as a working hypothesis,
that some chronic inflammatory and autoimmune diseases
could be considered for the purposes of investigation and
clinicopathological approach as models of chaperonopa-
thies by mistake. Among the latter, we may cite chronic
obstructive pulmonary disease [8], IBD [9], myasthenia
gravis [10], and other autoimmune diseases such as those
listed in Table 3 [11]. The interplay between the chaper-
oning and the immune systems of any given organism can
in principle occur at least in three ways, involving mech-
anisms pertaining to innate or adaptive immunity and cell
signaling in a hormonal fashion [12–14]. Other chaperon-
opathies by mistake are some forms of cancer, in which the
chaperones are involved in the carcinogenic steps, e.g., by
blocking apoptosis and favoring tumor cell growth by
various mechanisms [4, 15, 16]. In addition, tumor cells
can secrete HSPs, via exosomes and other ways, and the
released molecules most likely interact with specific targets
in the immune system [17, 18].
The intestinal microbiota: definition and biological
functions in health and disease
The human gut harbors about 100 trillion bacteria, and
more than 500 different species are present in the colon, so
the total personal bacterial concentration can reach
9 9 1013 numbers. The sum of these bacterial cells, which
form a ‘‘tissue in the organ’’, is termed the intestinal
microbiota. It resides in the gut of the host establishing a
mutually beneficial relationship and modulating, through
its metabolic activities, the host’s health status [19].
The microbiota exerts diverse physiological functions
such as inhibition of pathogenic bacteria and short fatty
acids synthesis; stimulation of nutrient and mineral
absorption, of the intestinal immune system and of gut
cellular renewal; synthesis of vitamins and amino acids;
and the decomposition of protein compounds [20, 21]. The
majority of bacteria composing the microbiota are not
pathogenic to the gut, but pathogenic species, for example,
Clostridia or Colibacillacea, are also present. A strictly
controlled balance between pathogenic and non-pathogenic
bacteria is crucial for maintenance of a physiological state
[22]. Alteration of the microbiota’s composition (e.g.,
abnormal expansion of one bacterial species with respect to
others) that may be caused by psychophysical, alimentary,
or environmental stress is defined as dysbiosis and may
lead to pathological conditions [23, 24].
Mounting experimental evidence shows an association
between microflora imbalance (i.e., dysbiosis) and IBD.
Among the various etiopathogenic hypotheses proposed,
one postulates that a change in the saprophytic microbial
flora is the primum movens, namely the primary stimulus,
which causes mucosal damage [25, 26]. Specifically, dys-
biosis leads to a modification of intercellular tight junctions
responsible for the correct structure of the epithelial layer
of intestinal mucosa. This inevitably leads to an increase in,
and change of, mucosal permeability [27]. Consequently,
penetration of antigens takes place into the intercellular
space leading to the activation of the mucosa-associated
lymphoid tissue (MALT), with recruitment and activation
of the inflammatory cascade (e.g., activation of leukocytes
and production of cytokines, such as TNF-alpha) and tissue
damage [25]. In addition, recent data provided evidence of
the ability of some components of the microbiota to acti-
vate Th17 cells in the small intestine lamina propria [28–
30].
An altered stimulation of the immune system leading to
inflammation may be a link between dysbiosis and meta-
bolic diseases. It has been proposed that in the obese and in
Table 3 Diseases in which HSP60 may act as autoantigen
Tissue/
organ
Cell/structure Pathology
Vessels Endothelial cells Vasculitis, atherosclerosis
Heart Myocardiocytes Myocarditis, infarct, heart
failure
Joints Synovial cells Rheumatoid arthritis
Pancreas Beta cells Diabetes
Thyroid Thyroid follicular cells Hashimoto’s thyroiditis
Liver Hepatocytes, biliary
ducts
Chronic active hepatitis,
primary biliary cirrhosis
Adrenal
glands
Glomerular zone cells Addison’s disease
Nervous
system
Synapses Myasthenia gravis
Kidney Endothelial cells
(glomerulus)
Glomerulonephritis
Skin Keratinocytes,
fibroblasts, endothelial
cells
Scleroderma, pemphigoid,
psoriasis, dermatomyositis
Modified from Cappello et al. [11], Campanella et al. [116]
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type 2 diabetes patients, a high-fat diet changes the gut
microbiota in a complex way, specifically decreasing
Bifidobacterium spp. This phenomenon is associated with
higher levels of lipopolysaccharides (LPS) in the plasma
(metabolic endotoxemia) and with a LPS-dependent
secretion of proinflammatory cytokines. High-fat diet and
LPS promote low-grade inflammation-induced metabolic
disorders (insulin resistance, diabetes, obesity, steatosis,
and infiltration of adipose tissue by macrophages) [31, 32].
The connection between microbiota composition and
metabolic disorders extends also to cardiovascular diseases
(CVD). Administration of a probiotic containing Lactoba-
cillus plantarum (Lp299v) and Bifidobacterium lactis
(Bi-07) reduced myocardial infarction in rats, which was
associated with a decrease in circulating leptin levels [33].
This suggests that altering the intestinal microbiota with
probiotics to decrease leptin levels in the circulation may
mitigate cardiac hypertrophy and enhance cardiac remod-
eling after myocardial infarction. An explanation of the link
between gut microflora composition and CVD could be the
ability of microbiota to metabolize dietary phosphatidyl-
choline (PC) generating trimethylamine that is converted in
the liver to trimethylamine N-oxide (TMAO) [34]. Inter-
estingly, associations were found between coronary artery
disease, peripheral vascular disease, and history of myo-
cardial infarction with the metabolites choline, TMAO, and
betaine [35]. Since an alteration in microbiota composition
may determine both intestinal and extra-intestinal pathologic
manifestations, it is not surprising that for almost 50 years,
the pharmaceutical industry has been proposing probiotics as
therapeutic agents for restoring the bacterial homeostasis of
the human intestine.
Probiotics: from definition to therapeutic use
The term probiotics was used for the first time in 1965 [36]. It
was reported that certain ‘‘substances’’ obtained from
intestinal segments, if placed in vitro with organic tissue,
stimulated the growth of the latter tissue. Subsequently,
further studies defined better the role of these ‘‘substances’’
identifying them as commensal intestinal bacteria. Today,
we tend to associate the term probiotics with microorgan-
isms, usually bacteria, producing beneficial effects on the
host. These bacteria are part of the normal intestinal microbial
flora acting as a commensal population, which distinguish
them from pathogenic bacteria, both exogenous (e.g., Sal-
monella, Shigella, Yersinia enterocolitica, etc.) and residents
(e.g., Bacilli, Clostridia, Klebsiella, Proteus, etc.) [20]. These
latter pathogenic organisms are not part of the normal flora or,
if present, they are only about 0.02 % of the total [37].
We know that administration of certain live bacteria can
have beneficial effects thanks to the ability of restoring the
intestinal microflora’s balance. Today, the pharmaceutical
industry, sensing the safe therapeutic potential of probio-
tics, studies and markets preparations of synergistic bac-
teria (Table 4). These probiotics generally include various
types of bacteria, such as Lactobacilli, Bifidobacteria, and
Enterococci, and are offered for therapeutic use in intes-
tinal and extra-intestinal pathologies [36]. In addition,
probiotic bacteria might find a use in the prevention of
cancers of the digestive tract [27, 36, 37]. Indeed, benefi-
cial effects of probiotics in the gastrointestinal tract have
been observed in experimental models of colon cancer. The
relationship between probiotics and cancer seems to be
based mainly on bacterial metabolism of various dietary
constituents leading to production of many compounds,
some of which may be carcinogenic and some anticarci-
nogenic [38, 39].
One of the best recognized uses of probiotics is for
diarrheal diseases, particularly in those cases of viral eti-
ology [38, 40]. In addition, probiotics are used as adjuvant
therapy in necrotizing enterocolitis [41], Clostridium dif-
ficile colitis [42], Rotavirus enteritis [43], gastric infection
by Helicobacter pylori [44], infection of urogenital appa-
ratus by Candida albicans [43], and in chronic inflamma-
tory diseases [45]. In chronic juvenile arthritis, gut defense
mechanisms are disturbed, and orally administered Lacto-
bacillus GG has potential to reinforce the mucosal barrier
[38, 46].
Probiotic bacteria have been shown to downregulate
inflammation associated with hypersensitivity reactions in
patients with atopic eczema and food allergy [38, 47].
Another unexpected benefit of probiotics is serum-lipid
reduction through their ability to take up cholesterol in the
presence of bile and in the absence of oxygen, both con-
ditions present in the intestinal tract [38, 48].
In view of all the observations listed above, we can
conclude that probiotics are versatile therapeutic tools with
promising potential to treat a variety of human diseases.
Probiotics are currently used mainly as ex-adiuvantibus
treatments, i.e., treatments with beneficial effects but
whose mechanism of action is unknown. Nevertheless, we
believe that if precise knowledge of the interactions
between probiotic bacteria and the cells of the human
intestinal mucosa becomes available, the efficaciousness of
probiotics to treat some specific conditions will increase. A
solid scientific basis of probiotic actions and interactions
will no doubt encourage their use in specific cases for
which they might appear indicated. An example of this
application may be inflammatory bowel diseases (IBD),
regarding which information has recently been gathered
[49, 50] indicating a close association between clinical
status, intestinal mucosa lesions, and immunological
parameters with levels of chaperones, such as HSP60, as
discussed below.
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Table 4 Effects of probiotics
Microflora Associated effects
Bacteroides species Chronic colitis, gastritis, arthritis (increased bacterial urease activity in chronic juvenile arthritis)
Bifidobacterium animalis Decreases Candida albicans systemic dissemination in euthymic or athymic beige mice
Bifidobacteria species Reduced incidence of neonatal necrotizing enterocolitis
Enterococcus faecium Escherichia
faecium
a. Decreased duration of acute diarrhea from gastroenteritis; b. No benefit in diarrhea due to Vibrio
cholerae and Escherichia coli
Escherichia coli non-pathogenic strain
(serotype O6:D5:H1)
As effective as mesalamine in maintaining remission of ulcerative colitis
Lactobacillus strains a. Administration of multiple organisms, predominantly Lactobacillus strains shown to be effective
in ameliorating pouchitis; b. Lactose digestion improved, decreased diarrhea and symptoms of
intolerance in lactose intolerant individuals, children with diarrhea, and in individuals with short-
bowel syndrome; c. Microbial interference therapy—the use of non-pathogenic bacteria to
eliminate pathogens and as an adjunct to antibiotics; d. Improved mucosal immune function,
mucin secretion, and prevention of disease
Lactobacillus acidophilus a. Significant decrease in diarrhea in patients receiving pelvic irradiation; b. Decreased Candida
albicans systemic dissemination in euthymic or athymic beige mice; c. Decreased polyps,
adenomas, and colon cancer in experimental animals; d. Prevented urogenital infection with
subsequent exposure to three uropathogens Escherichia coli, Klebsiella pneumoniae, and
Pseudomonas aeruginosa; e. Lowered serum cholesterol levels
Lactobacillus rhamnosus a. Reduced duration and/or risk of rotavirus diarrhea; b. Decreased polyps, adenomas, and colon
cancer in experimental animals; c. Reduced duration of acute diarrhea most often caused by
gastroenteritis; d. Reduced diarrheal illness in formula-fed toddlers; e. Reduced occurrence of
Clostridium difficile diarrhea; f. When co-administered with antibiotics in children, non-
Clostridium difficile antibiotic-associated diarrhea is reduced; g. Reduced risk of traveler’s
diarrhea; h. Reduced severity of pneumonia in children with cystic fibrosis; i. Decreased Candida
albicans systemic dissemination in euthymic; or athymic beige mice; j. Increased IgA-specific
antibody secreting cells to rotavirus and reduced the duration of diarrhea; k. Increased IgA
secretion in Crohn’s disease; l. Prevented recurrent, chronic vaginitis; m. Lactobacillus vaginal
suppositories effective in reducing the incidence of recurrent urinary tract infections; n. Reduced
food allergies and atopic dermatitis; o. Increased interleukin-10 production in atopic children
Lactobacillus fermentum strain KLD Traveler’s diarrhea: no effect
Lactobacillus plantarum Produced and preserved key nutrients, vitamins, and antioxidants; eliminated toxic components
from food; protected food from decay; eradicated pathogens such as Enterobacteriaceae,
Staphylococcus aureus and Enterococci
Lactobacillus plantarum (299v and DSM
9843)
a. Reduced incidence of diarrhea in daycare centers when administered to only half of the children;
b. Especially effective in reducing inflammation in inflammatory bowel, e.g., enterocolitis in rats,
small bowel bacterial overgrowth in children, pouchitis; c. Reduced pain and constipation of
irritable bowel syndrome; d. Reduced bloating, flatulence, and pain in irritable bowel syndrome in
controlled trial; e. Positive effect on immunity in HIV? children
Lactobacillus reuteri a. Shortened the duration of acute gastroenteritis; b. Decreased Candida albicans systemic
dissemination in euthymic or athymic beige mice; c. Prevented development of methotrexate-
induced and acetic acid-induced colitis in rats; d. Shortened acute diarrhea
Lactobacillus rhamnosus (HN001) Enhanced cellular immunity in healthy adults in controlled trial
Lactobacillus salivarius Suppressed and eradicated Helicobacter pylori in tissue cultures and animal models by lactic acid
secretion
Saccharomyces boulardii a. Reduced recurrence of Clostridium difficile diarrhea; b. Effects on Clostridium difficile and
Klebsiella oxytoca resulted in decreased risk and/or shortened duration of antibiotic-associated
diarrhea; c. Shortened the duration of acute gastroenteritis; d. Decreased only functional diarrhea,
but not other symptoms of irritable bowel syndrome; e. Decreased duration of diarrhea induced by
tube feedings; f. Ineffective for small intestinal bacterial overgrowth; g. May reduce HIV-related
chronic diarrhea; h. Childhood diarrhea; i. Extends remission time of Crohn’s disease; j. Increased
IgA anti-toxin A responses in pretreated mice
Saccharomyces cerevisiae Enhanced digestion of sucrose load was shown in infants with sucrase deficiency
Modified from Drisko et al. [38]
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Ulcerative colitis: a bowel disease with extra-intestinal
manifestations
Ulcerative colitis (UC) and Crohn’s disease (CD) are part
of the so-called IBD group [26] and constitute two major
healthcare problems pertinent to the digestive tract [51].
Mucosal inflammation may involve either all layers of
intestinal wall, as in CD, or only the mucosal and sub-
mucosal layers, as in UC [52]. In the intestinal mucosa of
patients with UC, the lamina propria is infiltrated by
abundant inflammatory cells, while the epithelium under-
goes cycles of destruction and repair by regeneration of
basal cells [49]. This aspect characterizes the clinical
course and the occurrence of complications of UC, dif-
ferentiating it from CD.
The etiology of IBD is still under investigation [53].
Inflammation of the intestinal wall is chronic and is due
probably to a complex interaction of genetic, microbial,
and environmental factors, which result in continuous
activation of gut-associated lymphoid tissue (GALT) [20].
Typical macroscopic lesions visible by endoscopy are
mucosal ulcerations with immune cell infiltration usually
accompanied by cryptic abscesses demonstrable by
microscopy in biopsies [20].
UC is an inflammatory disease characterized by a
chronic, recurrent clinical evolution [54]. Symptoms of UC
are bloody diarrhea and abdominal pain that may be
complicated by toxic megacolon [55]. Extra-intestinal
manifestations (EIM) of UC (Table 5) appear at least once
in 46.6 % of the patients and their prevalence may vary
depending on the geographic area in which the patient
resides [56]. The pathology of the joints manifested as
peripheral arthritis and arthralgia is the most common EIM
in UC [56]. Dermatological complications (e.g., psoriasis,
alopecia, and pyoderma gangrenosum) are present in 3.8 %
of UC patients [57]. Rare complications are glomerulone-
phritis, autoimmune hemolytic anemia, and celiac disease
[57]. Recto- or ano-vaginal fistulae complicating ulcerative
colitis [58] are rare but may occur in the patients with
severe rectal inflammation, and they can be managed by
restorative proctocolectomy with an ileal pouch anus or
anal canal anastomosis [59].
A protracted disease with persistent inflammation such is
the case in IBD may predispose to the development of
colorectal cancer [54]. The molecular mechanisms by which
inflammation promotes cancer development are still
incompletely understood and could differ from those
involved in non-colitis-associated forms of colorectal can-
cer. In this regard, a recent work has reported on the role of
distinct immune cells, cytokines, and other immune media-
tors in virtually all steps of colon tumorigenesis, including
initiation, promotion, progression, and metastasis [60].
Ulcerative colitis as a model of chaperonopathy:
evidences for and against it
HSPs have been found increased in UC, both in tissue and
serum [9, 61–63]. Pathological effects of HSPs in UC could
be due to one or more of the following mechanisms
(Fig. 1):
1. Non-disease-specific response to mucosal stress. The
inflamed colon tissue would react with a higher rate of
protein synthesis, and consequently, it would have a
pressing need for the folding of new polypeptides in
the face of protein destruction due to the pathological
process linked to inflammation. Self-HSPs would be
increased as a response to a situation in which the cell
needs more of them, but this situation would not
necessarily be typical of IBD since it can also occur in
other pathologies with inflammation and tissue
destruction [64–67]. Elevated levels of self-HSPs
would reflect an anti-pathogenic mechanism, and they
could be used as indicators of disease and, thus, could
have some value as diagnostic markers, and in
assessing prognosis and response to treatment.
2. The self-HSPs would form antigen–antibody com-
plexes because they are recognized by the patient’s
immune system as foreign, i.e., the HSPs have become
autoantigens due to, for instance, pathological post-
translational modifications that make the human mol-
ecules immunogenic with regard to its own immune
system [5]. The same consequences would occur if a
human (self) HSP shares antigenic epitopes and
immunologically cross-reacts with a foreign HSP
Table 5 Extra-intestinal manifestations of ulcerative colitis
Organ systems affected by
inflammation
Clinicopathological
manifestations
Musculoskeletal system Peripheral arthritis
Sacroiliitis
Ankylosing spondylitis
Osteoporosis
Skin Erythema nodosum
Pyoderma gangrenosum
Aphthous stomatitis
Eye Uveitis
Scleritis
Episcleritis
Hepatobiliary system Primary sclerosing cholangitis
Vascular system Thromboembolic events
Renal system Nephrolithiasis
Modified from Evans and Pardi [117]
Med Microbiol Immunol
123
ortholog from a bacterium present in the intestinal, or
respiratory, or genitourinary tract, or in the skin [11,
68, 69]. Accumulation of antigen–antibody complexes
in the intestinal mucosa would trigger inflammation
and tissue destruction [70–72]. In this situation, self-
HSPs would have a pathogenic effect, contrary to
cytoprotection. From the diagnostic viewpoint, mea-
surement of anti-HSP antibodies would help in deter-
mining the factors involved in pathogenesis, and this,
in turn, will suggest therapeutic strategies, such as
blockage of the immune system.
3. It is now known that, normally, self-HSPs reach the
blood and other body fluids and, thus, can interact with
components of the immune system [73]. Consequently,
macrophages, dendritic cells, and neutrophils are
activated and produce cytokines and chemokines,
eliciting and maintaining inflammation. Likewise, the
adaptive immune response can be activated. In both
situations, self-HSPs are agents of inflammation and
immune response.
In conclusion, taking into account the preceding
alternatives 2 and 3, self-HSPs could, indeed, be the eti-
ologic agent in UC or at least one of the primary etiologic
factors. The facts that HSP60 levels in the mucosa of UC
patients are increased, compared to the mucosa of healthy
individuals and significantly correlate with severity of
clinical manifestations support the notion that the chap-
eronin is involved in UC pathogenesis [9, 49, 50]. Fur-
thermore, UC treatment showed that the more clinically
efficacious is the treatment, the more marked is the
decrease in HSP60 (as well as in other inflammatory
markers) levels in the colon mucosa, to the point that in
complete remission the chaperonin levels are those typical
of the normal intestine [50]. Finally, also the number of
macrophages positive for HSP60 was reduced signifi-
cantly after therapy [50], the latter indicating that HSP60
may actively participate in triggering and/or maintaining
inflammation via macrophage stimulation, since these
cells bear HSP60-specific receptors [74, 75]. Therefore,
we postulated that UC can be regarded as a chaperon-
opathy, i.e., a disease in which chaperones are etiologic-
pathogenic factors [3, 7]. If self-HSPs in UC were
structurally no different from the normal molecules but
just increased due to dysregulation of their genes, UC
would be a pure dysregulatory chaperonopathy. However,
changes in gene expression levels are probably not the
only manifestation of disease since structural alterations
of the chaperone molecules themselves, for instance, due
to pathological post-translational modifications, might
also occur. To view UC from the standpoint afforded by
the chaperonopathy concept, as a working hypothesis,
offers an alternative to think on aspects of pathogenesis
Fig. 1 Proposed pathogenic mechanisms in ulcerative colitis (UC) in
which the chaperoning system plays a central role along with
imbalances in the gut microbiota. HSP60 is increased in the UC
mucosa (top left image) as compared with normal mucosa (bottom left
image) and may play a role against disease progression or,
alternatively, contribute to pathogenesis in at least two ways, as
depicted within the frames to the right. The photographs to the left
were taken from immunohistochemical preparations of colon mucosa
biopsies obtained from a patient with UC (top) and a normal control
(bottom). Primary antibody: anti-HSP60 (SIGMA, Milan, Italy);
clone: H4149; source: mouse; dilution: 1:300. Immunostaining kit:
avidin–biotin complex kit (LSAB2, DAKO, Carpinteria, CA). Chro-
mogen: 3,30-diaminobenzidine (DAB chromogen solution, DAKO).
Nuclear counterstaining: hematoxylin (DAKO). Bar 100 lm
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not much explored yet and, thus, opens the road for
developing novel tools for diagnosis, assessing prognosis
and response to treatment, and for exploring new thera-
peutic agents (for instance, compounds with the ability to
block the pro-inflammatory action of HSP60).
Effects of probiotics on UC remission and pathogenesis
In the last 15 years, a number of publications have reported
that probiotics can induce remission of UC symptoms but
their precise role in maintenance of remission is a matter of
debate [76]. In one study, for example, it was found that the
combination of balsalazide with a high-potency probiotic
mixture was the most effective treatment compared to
balsalazide alone and to mesalamine [77]. This study
considered several parameters, such as clinical symptoms,
endoscopy results, and histologic observations in the
evaluation of the three treatment modalities, all of which
tend to indicate that the data are comprehensive and reli-
able. Likewise, another study provided evidence of a dose-
dependent effect of probiotics administration in inducing
remission of the disease [78].
Probiotics produce their beneficial effects by various
mechanisms (Table 6). Firstly, they compete with other
luminal bacteria and prevent them from reaching the
lamina propria and stimulating the mucosal immune sys-
tem. Probiotics can also modulate intestinal barrier prop-
erties, regulating expression of genes encoding adherence
junction proteins [79–81]. Secondly, probiotics enhance
mucous production and, thus, protect the mucosa against
invasive bacteria.
Thirdly, probiotics stimulate the mucosal immune sys-
tem in the patient’s intestinal tract to secrete protective
immunoglobulins (Ig) such as secretory IgA and protective
defensins, and they produce bacteriocins into the lumen
[82]. It has also been shown that Lactobacillus brevis and
Streptococcus thermophilus selectively stimulate apoptosis
of mucosal immune cells counteracting the excessive
accumulation of these cells in the gut [83]. In this regard, it
is worth noting that excessive accumulation of mucosal
immune cells is believed to play a central role in IBD [84].
Fifthly, probiotics alter the function of the mucosal
immune system to make it more anti-inflammatory and less
pro-inflammatory [22, 26]. Along these lines, it has been
reported that an as yet elusive molecular mechanism trig-
gered by Lactobacillus plantarum prevents nuclear factor
kappa B (NFjB) binding in murine epithelial gut cells and
blocks the proteasome-dependent degradation of the NFjB
inhibitor IjBa [85].
Another set of data suggest also a role of probiotics in
regulating intestinal cell survival and growth. For instance,
proteins produced by Lactobacillus rhamnosus GG stimu-
lated protein kinase B (PKB/Akt) activation, promoted cell
growth, and inhibited tumor necrosis factor (TNF)-induced
epithelial cell apoptosis in cultured cells and in ex vivo
colon organ culture models [86]. It is pertinent to mention
here that a relationship does exist between microbiota and
intestinal cell turnover [21, 87] and that indigenous bac-
teria, in Drosophila melanogaster, can stimulate intestinal
stem cells to differentiate [88].
Effects of probiotics on HSPs levels in intestinal mucosa
of patients with UC
To the best of our knowledge, there are very few reports
describing the effects of probiotics on levels and
Table 6 Effects and possible mechanisms of probiotic treatment on IBD pathogenesis and remission: illustrative reports
Probiotics Molecular mechanism of action Therapeutic effects References
Streptococcus thermophilus and
Lactobacillus acidophilus
Activation of ERK isoforms Improvement of epithelial barrier
and transport properties
[79]
Lactobacillus acidophilus,
Lactobacillus fermentum,
Lactobacillus gasseri, and
Lactobacillus rhamnosus
Regulation of gene encoding E-cadherin and
b-catenin
Improvement of epithelial barrier
function
[85]
Lactobacillus brevis and
Staphylococcus thermophiles
Induction of mucosal immune cell apoptosis No excessive T cell accumulation
in the gut
[83]
Lactobacillus plantarum Inhibition of NFkB pathways Attenuation of inflammation [85]
Lactobacillus rhamnosus GG Regulation of antigen recognition by the intestinal
lymphoid tissue. Akt activation, inhibition of
cytokine-induced epithelial cells apoptosis
Attenuation of inflammation.
Improvement of epithelial
response to injury
[27, 86]
Lactobacillus salivarius plus
Lactobacillus acidophilus plus
Bifidobacterium bifidum BGN4
Reduction in levels of HSP10, HSP60, HSP70, and
HSP90 in inflamed mucosa. Reduction in levels of
CD68?/HSP60? cells in lamina propria
Amelioration of symptoms and
reduction in inflammation;
enhancing the effect of 5-ASA
[49, 50]
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expression of HSPs in intestinal mucosa of UC patients.
HSPs are important cytoprotectants when expressed intra-
cellularly in the epithelial cells of normal colonic mucosa
[64, 66]. For instance, HSP60 is specifically induced by
increments of colonic motility, 5-hydroxytryptamine
administration, thyrotropin-releasing hormone, and water-
immersion stress [89]. In addition, we and others collected
data by various techniques suggesting that HSPs might be
involved in UC pathogenesis [9, 61] and in colorectal
carcinogenesis as well [90–93]. We recently reported that
probiotics in combination with standard antibiotic therapy
significantly reduced the levels of HSP10, HSP60, HSP70,
and HSP90 in the mucosa of UC patients [49, 50]. This
reduction was more marked than that caused by the anti-
biotic alone (Fig. 2). These results were in accordance with
other studies that found increased HSP60 levels both in
mucosa and in sera of patients with UC [94–97]. In addi-
tion, we found that probiotic administration reduced sig-
nificantly the number of macrophages (CD68 ? cells)
positive for HSP60 in the lamina propria [50]. This result
was in agreement with data from other groups showing that
human HSP60 is elevated in mononuclear cells in the
mucosa of patients with UC [94] and that some HSP60-
derived peptides can stimulate an inflammatory response
via production of proinflammatory cytokines in the intes-
tinal mucosa of patients with CD [96]. Since it is known
that CD68-positive macrophages have receptors for HSP60
[97, 98] we hypothesize that HSP60 is taken up by CD68-
positive cells via those receptors, although we cannot
exclude that HSP60 may also be produced by the macro-
phages themselves. In case there was binding of HSP60 via
surface receptors, the expected consequence would be
activation of CD68-positive cells followed by an inflam-
matory response, as shown in in vitro models [98]. Finally,
probiotic therapy induced reduction in HSP60 down to
normal levels, or nearly so, in the cytosol of epithelial cells,
in which it increases in pathological situations, perhaps as a
prerequisite for its secretion [18]. Current studies aim to
elucidate the molecular links between probiotic adminis-
tration and reduction in HSP levels through gene expres-
sion and post-translational modifications. A possible
explanation could be that probiotics lower NFjB expres-
sion in intestinal cells [85] and in so doing lowering
expression of the hsp60 gene, a possibility suggested by the
finding that NFjB can bind to the hsp60 promoter and
thereby induce gene expression [8, 99].
Beneficial systemic effects of probiotics beyond
the bowel in UC
Probiotics, as well as commensal bacteria of a normal
bowel, can induce cytoprotective HSP expression by
secretion of polypeptides or other molecules that interact
with epithelial cells [100, 101]. In this way, HSPs partici-
pate in the normal anti-stress response of a healthy bowel.
However, when overexpressed in an inflamed mucosa, for
instance, during relapsing UC, human HSPs may be
released into the interstitium and thereby reach the
bloodstream in larger amounts than in healthy individuals.
In turn, this increase in circulating HSPs above the levels
that are tolerated by the immune system might elicit an
autoimmune response, thus being involved also in extra-
intestinal complications of UC.
In addition, invasion of the patient’s circulation by HSPs
released by the bacteria colonizing the colon mucosa (these
bacterial HSPs share antigenic epitopes with the human
Fig. 2 The levels of HSP60 detected by immunohistochemistry and
other methods in the colon mucosa of patients with UC are
considerably increased by comparison with those in the colon mucosa
from healthy controls but they decrease with treatment and clinical
improvement. Illustrative images (immunohistochemistry) pertaining
to a patient and a control are shown in the two top panels. Treatment
with mesalazine (bottom left) or with mesalazine and probiotics (PB)
(bottom right) decreased the levels of HSP60, more markedly in the
latter. This reduction correlated with clinical improvement (Mayo
score), which was also more pronounced with combined therapy.
Analogous results were obtained for HSP10, HSP70, and HSP90 (not
shown). For more details see [49, 50]. For technical details see legend
for Fig. 1. Bar 100 lm
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counterparts) is very likely to add to the antigenic burden
and raise it above the tolerogenic threshold, which results
in autoimmunity.
As described before, patients with UC may develop
systemic comorbidities and complications. Some of these
are autoimmune comorbidities that have been found asso-
ciated with increased levels of HSPs. For example,
increased levels of HSP70 and HSP90 have been impli-
cated in the onset of autoimmune arthritis [102–105], while
HSP70 has been linked to the development of autoimmune
hepatitis [106]. Clinical trials have been performed that
demonstrated the usefulness of HSP10 in reducing
inflammation in some autoimmune processes, such as
multiple sclerosis [107], severe plaque psoriasis [108], and
rheumatoid arthritis [109]. In addition, HSP90 inhibitors
have been proposed for the treatment for autoimmune
diseases involving inflammation and activation of the
adaptive immune response [105, 110].
Likewise, probiotics have been proposed for treating
extra-intestinal complications of IBD [111–114]. We
believe that the reduction in HSPs levels in the colonic
mucosa of patients with UC by probiotics reflects, at least
in part, the efficacy that probiotics might have in the
treatment for systemic complications. Microbiota exerts
important functions pertaining to the regulation of
homeostasis not only of the colon but also of the whole
organism, and adequate balance between the various
microbes is necessary for a healthy status. Furthermore,
certain non-pathogenic bacteria may favor development of
pathologic conditions, e.g., obesity, by providing metabo-
lites to other microbes in complex metabolic interactions
[115]. This new paradigm of pathogenicity ought to be
borne in mind in medical practice. Microbiota alterations
can occur during a number of pathologic, inflammatory
conditions including IBD. Treatment with probiotics may
contribute to the healing of an inflamed bowel by, for
instance, restoring the normal commensal flora. The latter
may have positive systemic effects by reducing the levels
of circulating pro-inflammatory molecules, including
HSPs. IBD are only an example of diseases in which
therapy with probiotics may lead to general benefits for the
human body.
It can be postulated that the use of these natural reme-
dies in medical therapy in lieu of, or in addition to,
Fig. 3 Working model for the triad probiotics–microbiota–chaper-
oning system, the latter represented by HSPs. The microbiota
composition must be balanced within the physiological range for
any given individual and pathogenic bacteria must be absent or at
least low and under control, as shown on top by the continuous line
indicating what should be the position of the scale arms leaning
toward the normal microbiota in healthy individuals. Overgrowth of
one or more bacterial populations, especially if they are pathogenic, at
the expense of the others with overproduction of HSPs may incline
the balance toward disease development, as indicated by the
discontinuous line. On the contrary, HSPs from the normal microbiota
(microbiota bacteria HSPs) and from the host (self-HSPs) would have
a beneficial regulatory effect on the immune system (immune
modulation) that would prevent deviation toward inflammation or
autoimmunity. If imbalances occur toward the pathogenic side, they
can be corrected with probiotics tailored to the specific needs of the
individual as shown on top by the curved arrow
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conventional drugs (e.g., antibiotics) deserves intensive
investigation by the scientific community in the forth-
coming years. For example, an unsolved point is to
establish which probiotic bacteria should be administered
in relation to which pathologic status in any given patient,
considering also the composition of his/her microbiota. A
great effort should be made in the future to find simple and
economic methods to assess the microbiota of each subject
during the various life periods, since we expect changes
during puberty, adulthood, and normal aging. A tailored
therapy with specifically targeted probiotics may be seen as
a novel approach to improving the ability to fight daily
stress and to reducing the probability of onset of a variety
of diseases, including chaperonopathies.
Conclusions
The current re-evaluation of the intestinal microbiota and
its importance in health and disease has also brought up to
light the potential of probiotics for its maintenance within
healthy limits. It is becoming clear that imbalances in the
subpopulations of the microbiota can lead to disease, so
there is a need to develop means for restoring the balance.
The wise use of probiotics might be one of those means. It
is also increasingly clear that the microbiota interacts with
the host, particularly with the intestinal mucosa, its cells,
and molecules. Among the latter are the components of the
chaperoning system, the HSP-chaperones, which have been
implicated as etiologic-pathogenic factors in inflammation
and autoimmunity. In addition, HSPs produced and
released into the host’s tissues and circulatory system by
pathogenic bacteria, HSPs that immunologically cross-
react with the human counterparts (self-HSPs), may be
immunogenic, determining acute and, in turn, chronic
inflammation as well as, in prone subjects, autoimmunity
and cancer development. HSPs produced and released by
microbiota, and by human cells (self-HSPs), might modu-
late immune reactions (e.g., by activating regulatory T
cells, Tregs) and arrest inflammation. In this way, probio-
tics may help to restore a healthy physiology of the
immune system, at least in the bowel interface between
external and internal environments (Fig. 3).
An integral view of the physiology and pathology of
immune disorders, such as IBD, and their treatment ought
to include the triad of microbiota–probiotics–HSPs. In
summary, physicians and pathologists as well as laboratory
professionals devoted to the study, management, and
treatment for diseases ought to become aware of this newly
defined group of pathological conditions, the chaperonop-
athies. This awareness will certainly hone their ability to
diagnose them correctly, which in turn will lead to better
patient management and disease control.
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